anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a polyphenol extracted from pistacia chinesis bunge seeds and an extraction method. The polyphenol is extracted by the following steps of: pistacia chinesis bunge seeds are used as raw materials and is added with an extracting solution according to a liquid to material ratio of between 1 to 3 and 1 to 200 g/ml. The mixture is leached for 1 minute to 7 hours under the conditions of a temperature of between 1 and 100 DEG C and a stirring speed of 0 to 1000 r/m and the pistacia chinesis bunge seeds are taken out. The solution is subject to centrifugation, volume determination, pressure reduction, concentration and distillation to remove the organic solvent. Thus a coarse polyphenol extract is obtained after vacuum freezing and drying. The invention adopts a solution extracting method using water, an acidic aqueous solution, an aqueous solution of an organic solvent or an aqueous solution of an acidic organic solvent as the extracting solution, with simple extraction conditions. The invention also uses ultrasonic waves or microwaves as an auxiliary means. Therefore, the extraction method can produce polyphonel with high yield rate, can improve the added value of processing and use of pistacia chinesis bunge and also provides a new resource for the polyphenol. As a result, the extraction method has good prospects in promotion and application.
INTRODUCTION: There is a lack of consensus on the management of inguinal hernia with limited symptoms. To address this issue a systematic review of existing randomized clinical trials (RCTs) was performed to critically appraise all existing data on asymptomatic hernia management, focusing on generalizability.
METHODS: A scoping review to identify all RCTs comparing surgical and conservative management of patients with inguinal hernias was undertaken. Medline, Embase, Cochrane and ClinicalTrials.gov databases were searched. Data collected included study characteristics and definitions of population, intervention/comparator, and outcomes; and limitations of each study were also extracted. The quality and generalizability of included RCTs were evaluated using Cochrane's ROB-2 and the PRECIS-2 tool, respectively.
RESULTS: Searches returned 661 papers; 14 full-text papers were assessed and three RCTs were identified. All RCTs included only male patients with a mean age above 55 years. All RCTs included asymptomatic patients and two included those with minimal symptoms. Different definitions for 'minimally symptomatic' were used in RCTs and none provided details of what was meant by conservative treatment. Follow-up periods varied between studies (1, 2, 3 years). All RCTs had an overall high risk of bias. According to PRECIS-2, two RCTs were classified as pragmatic, and one was equally pragmatic and explanatory.
DISCUSSION: This systematic review highlights a high risk of bias but a good generalizability of the findings from the RCTs conducted on minimally symptomatic inguinal hernia patients. To improve the guidelines for the management of this group of patients, more generalizable data are needed.
Single dose (600 mg) Gemfibrozil pharmacokinetics (i.e. plasma concentrations collected over time to calculate area under the concentration vs. time curve) assessed after 14.5 days of lopinavir/ritonavir (400/100 mg twice daily) administration.
Patients receive placebo PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo GI endoscopy with biopsy and collection of blood samples at screening and on study.
This intervention condition received no intervention from baseline (T0) to the second measurement point two weeks later (T2), Component A from T2 to two weeks later (T4), and Component B from T4 to two weeks later (T6). Target n = 7.
The invention provides a Miao medicine composition for radically curing tuberculosis, relating to the field of medicine. The Miao medicine composition comprises dried red date, cinnabar, vermilion, draconis sanguis, muscardine silkworm and centipede. After the Miao medicine composition is continuously perfected for decades, the number needed to treat is up to 1000, the effective rate reaches 100%, and the cure rate reaches 90% or above. Under the condition of application as required, the cure rate can reach 95% or above. The composition can quickly eliminate Mycobacterium tuberculosis, and can restore activities of tissues invaded by Mycobacterium tuberculosis to some extent. For severe patients with hemoptysis, bedriddenness and the like, the patients can do proper physical work without influencing daily life after being cured by the Miao medicine composition. Up to now, the longest radical cure time for the severe tuberculosis patients is 80 days, so the Miao medicine composition has the advantages of short cure period and favorable effects. More importantly, the Miao medicine composition basically does not damage the livers and kidneys. In view of the drug effects and the extent of injury of tuberculosis, the composition has very high market popularization and application values.
A method for the reduction in the risk of transmitting a sexually transmitted disease—especially HIV and/or HSV—during sexual activity is provided. This method generally comprises the application of an effective amount of an inhibitory agent, preferably as a topical formulation, to the area or areas of sexual contact prior to engaging in sexual activity. Inhibitory agents which are useful in the present invention include, for example, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H 2 SO 4 -modified mandelic acids, and the like. This method can be used by heterosexuals, homosexuals, and/or bisexuals engaged in a wide variety of sexual activities. In addition to anti-STD activity, these agents may also act as vaginal contraceptives; moreover, they generally have fewer side effects than conventional vaginal contraceptives (e.g., nonoxynol-9). For example, the compounds useful in this invention are generally not toxic to natural and beneficial vaginal flora and, thus, do not upset the local microbiological balance. The anti-STD method of the present invention has the added advantage that it can be implemented and controlled by either sexual party. Methods are also provided for reducing the risk of transmission of STD-causing organisms to health care providers and laboratory personnel (or other persons) who may come into contact with biological samples and specimens.
BACKGROUND: Saudi Arabia has one of the highest childhood obesity rates worldwide. The primary factor associated with the high prevalence of obesity among adolescents is a lack of physical activity (PA). Compared to male adolescents, very few Saudi female adolescents meet the World Health Organization recommendation of achieving 60 minutes of moderate-to-vigorous PA per day, putting them at a higher risk of overweight and obesity.
OBJECTIVE: This cross-sectional study aimed to examine the relationship between the theory of planned behavior and psychosocial factors, including attitude toward PA, subjective norms, perceived behavioral control (PBC), PA intention, and self-reported PA among Saudi female adolescents.
METHODS: A convenience sample of 329 Saudi female adolescents was recruited from all-female public intermediate and high schools in the Eastern Region of Saudi Arabia. Data were collected using online self-administered questionnaires. The theoretical model was examined using structural equation modeling.
RESULTS: The findings revealed a higher prevalence of overweight compared to obesity among participants. About half the participants were from families with a medium monthly income. The mean PA score indicated a low level of PA. The model demonstrated significant explanatory power for both PA intention and PA behavior, respectively. The strongest predictor of adolescents' intention was attitude, followed by PBC.Moreover, the female adolescents' attitudes and PBC had significant indirect effects on self-reported PA through intention, whereas intention had a direct effect on PA. The model did not support a direct or indirect relationship between subjective norms and PA.
DISCUSSION: The findings provide essential support for targeting attitude and perceived behavior control of female adolescents in order to enhance their PA intention. This theoretical understanding can help design effective theory-based interventions that promote PA among Saudi female adolescents.
BACKGROUND: Conventional nutritional metrics are closely associated with the prognosis of patients with radically resected esophageal squamous cell carcinoma (ESCC). Nevertheless, the prognostic implications of muscle and adipose tissue composite indexes in ESCC remain unknown.
METHODS: We retrospectively analyzed clinicopathological data of 304 patients who underwent resected ESCC. To obtain measurements of the muscle and adipose indexes, preoperative computed tomography (CT) images were used to quantify skeletal-muscle adipose tissue. The diagnostic threshold for muscle-adipose imbalance was determined using X-tile software and used to analyze the association between the muscle-adipose index (MAI) and survival. Instantaneous risk of recurrence was assessed using a hazard function. We constructed a nomogram based on the MAI and other clinical characteristics and established a novel predictive model with independent prognostic factors. The prognostic capabilities of these nomograms were evaluated using calibration curves, receiver operating characteristic (ROC) curves, and decision-curve analysis (DCA).
RESULTS: The overall survival (OS) and disease-free survival (DFS) rates in the muscle-adipose-balanced group were significantly better than those in the muscle-adipose-imbalanced group. Multivariate analyses revealed that the MAI, prognostic nutritional index (PNI), tumor stage, and tumor differentiation were independent prognostic factors for OS and DFS in patients with resected ESCC (P < 0.05). The nuclear density curve indicated a lower risk of recurrence for patients in the muscle-adipose-balanced group than that for their imbalanced counterparts. Conversely, the nuclear density curve for PNI was confounded. Postoperative radiotherapy- (RT) benefit analysis demonstrated that patients with ESCC in the muscle-adipose-balanced group could benefit from adjuvant RT.
CONCLUSION: This study confirmed that preoperative MAI could serve as a useful independent prognostic factor in patients with resected ESCC. A nomogram based on the MAI and other clinical characteristics could provide individualized survival prediction for patients receiving radical resection. Timely and appropriate nutritional supplements may improve treatment efficacy.
Compositions capable of producing heat on being mixed with water comprise dimethyl sulphoxide and a substantially non-aqueous gelling substance or soap, the dimethyl sulphoxide being present in an amount from 20-95% by weight of the total weight of the composition. The soap may be a fatty acid soap, e.g. stearate soaps, triethanolamine oleate, triethanolamine oleate soaps of coconut oil fatty acids, and of soya oil fatty acids, or one or a combination of synthetic detergents and thickeners, e.g. Promulgen G, a polyethylene glycol ether of a fatty acid, Pluracol V-10, a polyoxyalkylene polyol, Miranol and Ninol 128 Extra, a coconut fatty acid amide.  The words "Pluracol" and "Ninol" are Registered Trade Marks.  The soap compositions may be combined with aerosol propellants, e.g. n- or isobutane, propane, dichlordifluormethane, 1,2-dichlor - 1,1,2,2 - tetrafluorethane, monofluortrichlormethane, trichlortrifluorethane, or blends thereof, or nitrous oxide, nitrogen, and carbon dioxide. The aerosol soap compositions may also include mono- or poly-hydric alcohols as solubilizers, as well as foam stabilizers, lubricants, e.g. glyceryl esters, emollients, e.g. lanolin, and cetyl alcohol, perfumes and flavouring materials.  A preferred composition comprises dimethylsulphoxide, an alkaline shaving soap mixture, and a gelling substance comprising a copolymer of acrylic acid and polyallyl sucrose, e.g. Carbopol 934,940,941.  The word "Carbopol" is a Registered Trade Mark. The alkaline ingredient may be triethanolamine, diisopropanolamine, or alkali metal hydroxide. The compositions of the invention may be used to formulate de-icing compositions.ALSO:Compositions capable of producing heat on being mixed with water comprise dimethyl sulphoxide and a substantially non-aqueous gelling substance or soap, the dimethyl sulphoxide being present in an amount of 20-95% by weight of the total weight of the composition.  Pharmaceutical components may be added to the dimethyl sulphoxide compositions which contain the gelling substance together with conventional excipients. Preferred gelling substances are copolymers of acrylic acid and a polyallyl sucrose, e.g. Carbopol 940, 941, and 934 (the word "Carbopol" is a Registered Trade Mark). Examples are given of analgesic and aromatic chest rubs, the ingredients of the formulations including methyl salicylate, benzocaine, glycol monosalicylate, methyl nicotinate, capsicum oleoresin, camphor, menthol, thymol, encolyptol, pine oil, clove oil, diisopropanolamine, polyethylene oxide sorbitan mono-oleate and histamine dihydrochloride, choline salicylate, turpentine, sassafras, hyoscyamus extract and oil of mustard may also be added.  The compositions of the invention may be used in preparing hand lotions and creams as well as pharmaceutical compositions for both topical and internal application.  The compositions may contain some water, provided that the amount is sufficiently low for the compositions to evolve heat on subsequent mixing with water.  The soap component may be one or a combination of synthetic detergents or a fatty acid soap, e.g. triethanolamine oleate.
PURPOSE:To obtain a percutaneous absorption cataplasm capable of developing an anesthetic effect in a short time after attaching by laminating a tacky agent layer consisting of a tacky agent, lidocaine, isopropyl myristate on one surface of a support. CONSTITUTION:This cataplasm is obtained by laminating a tacky agent layer consisting of 100 pts.wt. of a tacky agent [e.g. a (meth)acrylic acid alkylester copolymer], 5-100 pts.wt. of lidocaine which is a local anesthetic and 5-150 pts.wt. of isopropyl miristate on one surface of a support [e.g styreneisoprene- styrene block copolymer]. Further, an organic acid, a fatty acid ester, surfactant, amine amide, etc., may be added to the tacky agent layer. Since percutaneous absorption of the local anesthetic is promoted by adding isopropyl miristate to the tacky agent layer, anesthetic effect can be obtained in a short time and the cataplasm causes no deposition of crystals in the tacky agent or leaves no paste on the skin. The cataplasm is used for local anesthesia in arteriovenous indwelling catheter treatment before operation and local anesthesia before dura or lumbar puncture, arthrosis puncture or small operation of skin to remarkably relieve pains of patients.
SNRIs, including levomilnacipran, have been associated with increased heart rate. Heart rate should be measured prior to initiating treatment and periodically throughout levomilnacipran treatment. Pre-existing tachyarrhythmias and other cardiac disease should be treated before starting therapy with levomilnacipran. For patients who experience a sustained increase in heart rate while receiving levomilnacipran, discontinuation or other appropriate medical intervention should be considered.

In short-term clinical studies, levomilnacipran treatment was associated with a mean increase in heart rate of 7.4 beats per minute (bpm) compared to a mean decrease of 0.3 bpm in placebo-treated patients. Heart rate increase in levomilnacipran-treated patients receiving doses of 40 mg, 80 mg and 120 mg was 7.2, 7.2, and 9.1 bpm. 

Levomilnacipran has not been systematically evaluated in patients with a cardiac rhythm disorder.
BACKGROUND: Lung adenocarcinoma (LUAD) is the most common type of lung cancer, and its pathogenesis remains not fully elucidated. Inflammation and metabolic dysregulation are considered to play crucial roles in LUAD development, but their causal relationships and specific mechanisms remain unclear.
METHODS: This study employed a two-sample Mendelian randomization (MR) approach to systematically evaluate the causal associations between 91 circulating inflammatory factors, 1,400 serum metabolites, and LUAD. We utilized LUAD genome-wide association studies (GWAS) data from the FinnGen biobank and GWAS data of metabolites and inflammatory factors from the GWAS catalog to conduct two-sample MR analyses. For the identified key metabolites, we further used mediator MR to investigate their mediating effects in the influence of IL-17A on LUAD and explored potential mechanisms through protein-protein interaction and functional enrichment analyses.
RESULTS: The MR analyses revealed that IL-17A (OR 0.78, 95%CI 0.62-0.99) was negatively associated with LUAD, while 71 metabolites were significantly associated with LUAD. Among them, ferulic acid 4-sulfate may play a crucial mediating role in the suppression of LUAD by IL-17A (OR 0.87, 95%CI 0.78-0.97). IL-17A may exert its anti-LUAD effects through extensive interactions with genes related to ferulic acid 4-sulfate metabolism (such as SULT1A1, CYP1A1, etc.), inhibiting oxidative stress and inflammatory responses, as well as downstream tumor-related pathways of ferulic acid 4-sulfate (such as MAPK, NF-κB, etc.).
CONCLUSION: This study discovered causal associations between IL-17A, multiple serum metabolites, and LUAD occurrence, revealing the key role of inflammatory and metabolic dysregulation in LUAD pathogenesis. Our findings provide new evidence-based medical support for specific inflammatory factors and metabolites as early predictive and risk assessment biomarkers for LUAD, offering important clues for subsequent mechanistic studies and precision medicine applications.
In group 3 the plastic stage is performed: on one side of the perineal wound, a cutaneous-subcutaneous-fascial flap on the leg is cut out and deepithelized, along the entire length of the wound, thereby forming a diamond-shaped perineal wound, plunging it into the pelvic aperture, fixing it with single sutures to the remnants of the muscle lifting the anus of the opposite side, and the flap width is 3-4 cm to fill the pelvic aperture. On the opposite side of the wound, a triangular skin-subcutaneous fascial flap is cut out on a leg equal to the width of the previously formed diamond-shaped wound at an angle of 60-80 degrees from the middle of the wound edge, and the sides of the triangular flap should be equal to half the length of the edge of the diamond-shaped wound, then it is moved and additionally fill the wound cavity with it, in condition of displacement of the apex of the triangle flap with the top of the rhombus-wounds. The flap is fixed with separate skin nodular sutures.
Abuse and Dependence: Butalbital: Barbiturates may be habit-forming: Tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. As this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. The lethal dose of a barbiturate is far less if alcohol is also ingested. Major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. One method involves initiating treatment at the patient's regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.
A method for enhancing extracellular vesicle production is described. A peptide that induces polymer formation is incubated with a cell culture which results in enhanced EV production. The peptide penetrates the cells and subsequently polymerizes upon exposure to enzymes (e.g. phosphatase) within the cell. The cells that contain the newly formed polymers have an increased production of EVs. These EVs can be harvested using centrifugation techniques.
ONC201 (TIC10) is a first-in-class small molecule that inactivates the Ras effector target kinases, Akt and ERK, selectively in tumor, but not normal, cells to safely trigger cancer cell death. The dual inactivation of Akt and ERK by ONC201 results in broad-spectrum cytotoxic activity that includes activation of TRAIL-mediated apoptotic and other downstream antitumor effects to produce a potent antitumor response. The safety margin (ratio of therapeutic dose to lowest dose with a mild adverse event) of ONC201 is at least 10-fold in rats and dogs in GLP toxicology. The efficacy of ONC201 has been consistently demonstrated in multiple in vitro, ex vivo, and in vivo preclinical cancer models. Favorable attributes of ONC201 observed in preclinical models include antitumor efficacy with infrequent administration, broad-spectrum activity independent of mutations or tumor type, orally active, high safety margins, synergistic activity with many approved therapies, highly stable, highly water soluble, and ability to penetrate the blood-brain barrier. In the phase I portion of the trial, the hypothesis is that ONC201 will exhibit an acceptable safety profile in patients with advanced cancer. In the phase II portion of the trial, the hypothesis is that ONC201 will show preliminary signs of efficacy in patients with advanced cancer as defined by endpoints that include progression-free survival, response rate, biomarkers, and overall survival.
Patients receive bevacizumab IV on day 1 of each cycle. Treatment repeats every 3 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy and blood sample collection throughout the study.
Patients with persistent or long-standing persistent atrial fibrillation will be enrolled in this multi-center, randomized, prospective, single-blinded study. All patients are required to be in atrial fibrillation (AF) on the day of the ablation procedure. After ablation (isolation) of the pulmonary veins (PVI) is complete, and while still in the electrophysiology lab, all patients are randomized to either PVI, alone \[Group 1\] or the combination of PVI plus ablation of the posterior left atrial wall (PLAW) \[Group 2\]. For those patients randomized to PVI, their ablation procedure is complete at this time. For those patients randomized to PVI plus PLAW, they will have the additional ablation to the posterior left atrial wall performed.

All study patients have the same follow-up after their ablation procedure: clinic visits at 3, 6, and 13 months; a heart event monitor is worn for 7-14 days before these visits. An echocardiogram is done at 4-6 months after the ablation procedure. Blood thinners are usually recommended for three months after the ablation procedure and then the need for continued use of blood thinners will be based on individual patient's medical history, stroke risk and the judgement of their study doctor. Information about patient's medical history, heart arrhythmias, and atrial fibrillation will be collected during the study. This information will be analyzed as part of the study.
Intervention: Lungrecruitment in prone position. Device: Ventilator Flow-i, Peak inspiratory pressure 40 cmH2O, PEEP 20 cm H2O during 30 s.